Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

Inclusion Criteria: Male/Female aged 6-13 years of age Diagnosis of SAR/PAR, with symptoms within the past 3 months Positive skin test to inhalant allergen with negative saline control No previous use of intranasal inhaled, oral, IV or topical steroid use within past 6 months. If the subject has asthma, only mild intermittent (per NAPP) guidelines treated with PRN bronchodilator Exclusion Criteria: screening height outside the 5th and 95th percentiles History of abnormal growth Any other chronic condition beside allergic rhinitis or mild intermittent asthma Subject who has insufficient allergic rhinitis symptoms to require daily therapy during the trial. Subject with a known hypersensitivity to any active ingredients or excipents in the study medications Subject with nasal candidiasis, acute or chronic sinusitis, significant nasal polyposis (impairs nasal breathing), or other gross anatomical deformity of the nose sufficient to impair nasal breathing (e.g., deviated septum) Subjects with a history of substance abuse, mental illness or retardation Subjects with a history or presence of glaucoma or posterior subcapsular cataract Subjects with nocturnal enuresis. Use of Theophylline, Intal/Tilade or leukotriene modifiers.